Injectable Semaglutide Produces Nearly Twice the Weight Loss of the Pill Version Over Two Years | Research

The takeaway

In a real-world comparison of 367 type 2 diabetes patients over two years, subcutaneous semaglutide produced 7.5% body weight loss versus 4.4% for oral semaglutide, with significantly more patients achieving 10% or greater weight loss with the injection.

7.5% vs 4.4% weight loss over 2 years
Subcutaneous semaglutide produced nearly twice the percentage weight loss compared to oral semaglutide in real-world type 2 diabetes patients

What the researchers found

Over two years, subcutaneous semaglutide users (n=310) lost a mean 7.5% body weight (16.7 pounds), while oral semaglutide users (n=57) lost 4.4% (8.7 pounds) — a statistically significant difference (p<0.01). For the clinically meaningful threshold of ≥10% weight loss, 32.9% of injection users achieved it versus 17.5% of pill users (p=0.03).

The proportion achieving ≥5% weight loss was not significantly different between formulations (58.7% vs 50.9%, p=0.34). An unexpected finding was an age effect within oral semaglutide users: older patients achieved better weight loss than younger ones (p=0.02), a pattern not seen in the subcutaneous group. Regression analyses adjusting for confounders confirmed these findings.

Why it matters

Many patients prefer pills over injections, and oral semaglutide was developed specifically to address this preference. However, this real-world data shows that the convenience of the pill comes with a meaningful trade-off in weight loss effectiveness — patients lose roughly half the weight compared to the injection over two years. This information is crucial for informed shared decision-making between clinicians and patients, particularly when weight loss is a primary treatment goal.

How the study worked

This was a retrospective cohort study using a real-world database, comparing adults with type 2 diabetes who received subcutaneous semaglutide (n=310) versus oral semaglutide (n=57) over a 2-year treatment period. Weight loss was evaluated through mean percentage change from baseline and proportion achieving ≥5% and ≥10% weight loss. Results were analyzed by formulation and by age group, with regression analyses adjusting for confounding variables.

What this study cannot tell us

The oral semaglutide group (n=57) was much smaller than the subcutaneous group (n=310), reducing statistical power for subgroup analyses. As a retrospective observational study, it cannot establish causation — the two groups may differ in unmeasured ways despite regression adjustment. Adherence to the strict oral semaglutide dosing protocol was not measured. The oral semaglutide doses available at the time (up to 14 mg) were lower than the newer 25 mg and 50 mg formulations now in development, which may narrow the efficacy gap. Reasons for choosing oral versus subcutaneous were not captured.

How to read the evidence

This is a retrospective real-world cohort study, which provides important effectiveness data outside clinical trial conditions but has inherent limitations including potential selection bias and confounding. The unequal group sizes (310 vs 57) further limit comparison power.

When this study was published

Published in 2025, this is one of the first studies providing 2-year real-world comparative data between oral and subcutaneous semaglutide formulations, making it highly timely and relevant.

The bigger picture

As GLP-1 receptor agonists become the dominant pharmacological approach to obesity and type 2 diabetes, understanding the real-world performance gap between formulations is critical for healthcare systems, payers, and patients. Clinical trials suggested differences between oral and injectable semaglutide, but real-world data often diverges from trial results due to adherence challenges, patient selection, and the strict dosing requirements of oral semaglutide (empty stomach, limited water, 30-minute fast). This study adds important long-term real-world evidence to inform these decisions.

Questions still open

Would higher-dose oral semaglutide formulations (25 mg or 50 mg) close the efficacy gap with the subcutaneous version?
Why do older patients respond better to oral semaglutide — is it adherence to dosing instructions, metabolic factors, or differences in body composition?
Should clinicians more actively recommend switching from oral to subcutaneous semaglutide when patients aren't achieving weight loss goals?

Common questions

Is the semaglutide pill just as good as the injection for weight loss?

This real-world study found that the injection works meaningfully better for weight loss over two years: 7.5% body weight loss with the injection versus 4.4% with the pill. About a third of injection users lost 10% or more of their weight, compared to fewer than one in five pill users. The difference may partly reflect the strict dosing requirements of the pill (empty stomach, limited water, 30-minute wait), which can be hard to follow consistently.

Why might older patients do better on oral semaglutide than younger patients?

The study found that older oral semaglutide users lost more weight than younger ones, a difference not seen with the injection. While the exact reason is unknown, it may relate to better adherence to the strict dosing protocol among older adults, who may have more structured morning routines, or differences in metabolism and body composition that favor the oral formulation's effects.

Read the original research

Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.

Expert review of endocrinology & metabolism, 20(2), 163-168

View on PubMed ↗Publisher’s paper ↗

Citation

Kwon, Jimmy; Thiara, Diana; Watanabe, Jonathan H. (2025). Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.. Expert review of endocrinology & metabolism, 20(2), 163-168. https://doi.org/10.1080/17446651.2025.2462100